You are here : Home > GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients

Publications CNRGH

GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients

Published on 2 October 2023
GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients
Description
 
Date de publication 
Auteurs
Cox DG, Curtit E, Romieu G, Fumoleau P, Rios M, Bonnefoi H, Bachelot T, Soulie P, Jouannaud C, Bourgeois H, Petit T, Tennevet I, Assouline D, Mathieu MC, Jacquin JP, Lavau-Denes S, Darut-Jouve A, Ferrero JM, Tarpin C, Levy C, Delecroix V, Trillet-Lenoir V, Cojocarasu O, Meunier J, Pierga JY, Faure-Mercier C, Blanche H, Sahbatou M, Boland A, Bacq D, Besse C, Deleuze JF, Pauporte I, Thomas G and Pivot X
Revue
Année2,016
Département / Service
IG/CNG
Laboratoire
LBanq, LHD, LBInf
Impact Factor5.17
InstitutIG
url DOI10.18632/oncotarget.12669

Go back to list